Obesity/Overweight – Current Treatment – Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. The most frequently used first-line therapy remains generic phentermine, a drug that has been on the U.S. market for decades. However, since 2012, a number of novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), Eisai’s Belviq (lorcaserin), and Nalpropion Pharmaceuticals’ Contrave (naltrexone / bupropion). This report provides important insights into how prescription weight-loss agents are used in the management of obesity and how practices are evolving.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed obese / overweight patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed obese patients?
  • How has Saxenda been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of obese / overweight patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of obese / overweight patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Novo Nordisk, Vivus, Eisai, Nalpropion Pharmaceuticals

Key drugs: Saxenda, Qsymia, Contrave, Belviq, Xenical, phentermine

Table of contents

  • Obesity/Overweight - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
    • Treatment Algorithms CDA Obesity US June 2021
    • Treatment Algorithms CDA Obesity US 2021 Dashboard

launch Related Market Assessment Reports